A new light-driven cancer therapy uses LEDs and tin nanoflakes to kill tumors safely and affordably. Developed by teams in Texas and Portugal, it eliminates up to 92% of skin cancer cells without ...

Scientists at University of California San Diego have developed a new approach to destroying cancer stem cells—hard-to-find cells that help cancers spread, come back after treatment and resist therapy ...

Cancer thrives by hijacking the body's own basic survival systems, making it hard to attack tumors without collateral damage and side effects. Now, researchers at Cornell's Weill Institute for Cell ...

Lung cancer remains the leading cause of cancer-related death in the United States. The good news is that early detection through screening, combined with advancements in treatment, significantly ...

Oct. 14, days before the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Merck & Co. | Merck has just registered the 15th global phase 3 trial for its TROP2 antibody-drug ...

A drug from AstraZeneca and Daiichi Sankyo has succeeded in a large clinical trial focused on aggressive, hard-to-treat breast cancer, opening the door to a possible approval for one of the toughest ...

Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the cancer benefit from immunotherapy with atezolizumab compared to placebo whereas ...

Researchers from the Alliance for Clinical Trials in Oncology have found that two targeted immunotherapy drugs lead to high remission rates and long survival with reasonable side effects for older ...

Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the strength ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced ...

(UroToday.com) The 2025 European Society for Medical Oncology (ESMO) Annual Congress held in Berlin, Germany was host to a prostate cancer poster session. Dr. Deepak Kilari, presented an analysis of ...

Title: Biparatopic anti-HER2 antibody drug conjugate (ADC) JSKN003 in the treatment of primary platinum-refractory ovarian cancer (OC) Presentation Number: 1079P Onsite Poster display date: Saturday, ...